89bio Pharma (ETNB) - Long-Term Debt to Capital Coefficient

This price chart for 89bio, Inc. (ETNB) reflects the company's dynamics, where the indicator stands at 0.07. The business is currently constrained by a lack of operating leverage due to clinical trials, which increases unit costs prior to commercialization. Stable demand for liver therapy guarantees long-term patent revenue, while the firm simultaneously implements advanced treatments for rare metabolic disorders to fill vacant market niches.

For the biotechnology company 89bio, Inc. (ETNB), which generates no revenue and depends on the outcome of clinical trials, managing debt load is critical to preventing default. The ratio of liabilities with a maturity of more than one year to equity measures financial leverage, which allows for an assessment of share dilution risk when seeking new financing via the current long-term debt-to-equity level on GURU.Markets.